Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Stage 0 Breast Cancer AJCC v6 and v7: early-phase trial registry
A small indexed set (3 trials) with no open enrollment listed right now.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · none currently recruiting · #5,209 of 28,707 conditions by registered trial count
Stage 0 Breast Cancer AJCC v6 and v7: 3 US clinical trials tracked, none currently recruiting.
Stage 0 Breast Cancer AJCC v6 and v7 is the subject of 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 2 of these trials.
Enrollment posture brief
Registry condition stage-0-breast-cancer-ajcc-v6-and-v7
OPEN 0 | RECR 0% | LATE 1 | EARLY 2 | RANK #5209 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Stage 0 Breast Cancer AJCC v6 and v7 has no open enrollment in this registry pull (3 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Stage 0 Breast Cancer AJCC v6 and v7 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Stage 0 Breast Cancer AJCC v6 and v7 is recruiting below its size-band peers.
0 of 3 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
3 total, page 1 of 1
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
National Cancer Institute (NCI)
NCT02954874
Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer
M.D. Anderson Cancer Center
NCT01245712
Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery
National Cancer Institute (NCI)
NCT03317405
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Stage 0 Breast Cancer AJCC v6 and v7 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Stage 0 Breast Cancer AJCC v6 and v7 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Stage 0 Breast Cancer AJCC v6 and v7 page
3 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Stage 0 Breast Cancer AJCC v6 and v7 trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- National Cancer Institute (NCI) sponsors the most Stage 0 Breast Cancer AJCC v6 and v7 trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage 0 Breast Cancer AJCC v6 and v7 condition card totals 3 registered trials; most-linked intervention Quality-of-Life Assessment; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.